IRIS
SERVETTO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 501
EU - Europa 398
AS - Asia 80
AF - Africa 27
Totale 1.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 498
IT - Italia 311
CN - Cina 40
NL - Olanda 34
CI - Costa d'Avorio 27
IN - India 19
IE - Irlanda 13
FR - Francia 12
DE - Germania 10
PK - Pakistan 10
FI - Finlandia 9
VN - Vietnam 4
CA - Canada 3
GB - Regno Unito 3
IR - Iran 3
GR - Grecia 2
MY - Malesia 2
SE - Svezia 2
BE - Belgio 1
ES - Italia 1
JP - Giappone 1
UZ - Uzbekistan 1
Totale 1.006
Salva come PNG Salva come JPEG
Città #
Chandler 90
Naples 89
Ashburn 64
Napoli 48
Amsterdam 34
Millbury 24
Lawrence 16
Beijing 15
Des Moines 14
Pune 13
Boston 12
Princeton 10
Hicksville 9
Formia 8
Nanjing 8
San Mateo 8
Modica 7
Seattle 7
Wilmington 6
Milan 5
Nanchang 5
Turin 5
Caserta 4
Dong Ket 4
Fucecchio 4
Hebei 4
Islamabad 4
Lahore 4
Rome 4
Salerno 4
San Giorgio a Cremano 4
Woodbridge 4
Amalfi 3
Angri 3
Ardabil 3
Casagiove 3
Castel San Giovanni 3
Fairfield 3
Mumbai 3
Ottawa 3
Pizzo 3
Council Bluffs 2
Duncan 2
Genoa 2
Harbin 2
Krefeld 2
Kuala Lumpur 2
Lappeenranta 2
Lomazzo 2
Luco dei Marsi 2
Palma Campania 2
Pozzuoli 2
Prato 2
Pátrai 2
Rawalpindi 2
Redwood City 2
Augusta 1
Bangalore 1
Casalnuovo 1
Casoria 1
Changchun 1
Changsha 1
Cologne 1
Dublin 1
Falkenstein 1
Giugliano In Campania 1
Hanover 1
Houston 1
Indiana 1
Jacksonville 1
Jiaxing 1
Kagoya 1
La Canada Flintridge 1
La Louvière 1
Lanuvio 1
Leawood 1
Legnano 1
Los Angeles 1
Marcianise 1
Marigliano 1
Mirabella Eclano 1
Montalbano Jonico 1
Mountain View 1
Nashville 1
Paris 1
Pomigliano d'Arco 1
Redmond 1
San Giorgio A Cremano 1
San Jose 1
San Mango Piemonte 1
San Marzano sul Sarno 1
San Sebastiano al Vesuvio 1
Sant'Elia Fiumerapido 1
Santa Maria Capua Vetere 1
Sesto Fiorentino 1
Shenyang 1
Tashkent 1
Washington 1
Witney 1
Yellow Springs 1
Totale 638
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 84
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 56
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 56
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 53
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 46
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 42
Mechanisms of resistance to mTOR inhibitors 42
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 41
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 40
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 38
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 37
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 36
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 35
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 33
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 29
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 28
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 27
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 27
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 25
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 25
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 25
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 24
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 23
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 23
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 22
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 21
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 21
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 20
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 19
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 18
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity 17
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 16
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 15
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 14
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 8
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 7
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer 6
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 4
Totale 1.103
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202099 25 0 5 10 13 8 0 7 1 8 15 7
2020/202195 3 0 2 0 11 6 4 6 19 14 19 11
2021/2022183 5 0 8 10 4 9 4 4 32 17 38 52
2022/2023347 35 11 15 9 45 36 14 31 51 42 34 24
2023/2024282 14 34 61 22 17 54 23 36 9 10 2 0
Totale 1.103